Anti-mog (myelin oligodendrocyte glycoprotein) antibodies for the diagnosis of optic neuromyelitis and other demyelinating diseases
Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32016000908
Spanish
Authors' recommendations:
The evidence on the usefulness of myelin oligodendrocyte glycoprotein antibody test to diagnose optic neuromyelitis is of low quality. No studies assessing the accuracy of this test in differentiating this disease from multiple sclerosis or other demyelinating diseases have been found. Its use is proposed when diagnosis cannot be made using the specific anti-aquaporin-4 antibodies test but even in theses cases, there is not enough evidence to ensure its usefulness. In addition, there is not enough evidence to support its role in clinical prognosis of these diseases. The clinical practice guidelines surveyed do not consider its use or consider it of uncertain usefulness. The health sponsors surveyed consider this technology as experimental.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Antibodies
- Myelin-Oligodendrocyte Glycoprotein
- Neuromyelitis Optica
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.